| A comparative evaluation of tretinoin gel microsphere, 0.1%, versus tretinoin cream, 0.025%, in reducing facial shine. | |
| | |
MedLine Citation:
|
PMID: 10955199 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Tretinoin gel microsphere, 0.1%, is a highly effective anti-acne medication formulated with sponge-like microspheres encapsulating the active ingredient, tretinoin. In addition to minimizing cutaneous irritation, this system may also reduce facial shine. This single-center, double-blind, half-face study evaluated the potential of tretinoin gel microsphere, 0.1%, to reduce the appearance of facial shine compared to tretinoin cream, 0.025%. Thirty-five subjects (ages 12 to 24 years) with moderate acne vulgaris and moderate facial oiliness, were evaluated after 4 consecutive days of product use. On sides treated with tretinoin gel microsphere, 0.1%, investigators found significantly reduced facial shine at 3 and 6 hours posttreatment. Subjects' self-evaluations revealed a significant reduction in facial shine at 3 hours posttreatment. Photographic analyses showed reductions in facial shine for both treatments, but decreases were greater on tretinoin gel microsphere, 0.1%-treated sides. Both therapies were well tolerated, and no adverse events occurred. Tretinoin gel microsphere, 0.1%, has the added benefit of reducing the appearance of facial shine, which is a frequent concern in acne patients. |
| | |
Authors:
|
J Nyirady; M Nighland; G Payonk; J Pote; S Phillips; R Grossman |
Related Documents
:
|
21993709 - What information do cancer genetic counselees prioritize? 11571349 - Diagnostic accuracy and certainty from sequential evaluations in peripheral neuropathy. 15223169 - Predictive value of hysteroscopic examination in intrauterine abnormalities. 21923459 - Understanding risk evaluation and mitigation strategies in organ transplantation. 21869169 - Emerge-a data-driven medical decision making aid. 9129699 - Cd34 and factor-xiiia immunoreactivity in dermatofibrosarcoma protuberans and dermatofi... 2432549 - Is reuse financially worthwhile? 20165529 - Integration of evidence based medicine into a medical curriculum. 15332069 - Resuscitating the physician-patient relationship: emergency department communication in... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Cutis; cutaneous medicine for the practitioner Volume: 66 ISSN: 0011-4162 ISO Abbreviation: Cutis Publication Date: 2000 Aug |
Date Detail:
|
Created Date: 2000-12-04 Completed Date: 2000-12-14 Revised Date: 2009-11-11 |
Medline Journal Info:
|
Nlm Unique ID: 0006440 Medline TA: Cutis Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 153-6 Citation Subset: IM |
Affiliation:
|
Johnson & Johnson Consumer Products Worldwide, Skillman, NJ 08558-9418, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acne Vulgaris
/
drug therapy*,
metabolism Administration, Topical Adolescent Adult Child Double-Blind Method Face Female Gels Humans Keratolytic Agents / administration & dosage* Lipids / biosynthesis Male Ointments Skin / drug effects*, metabolism Tretinoin / administration & dosage* |
| Chemical | |
Reg. No./Substance:
|
0/Gels; 0/Keratolytic Agents; 0/Lipids; 0/Ointments; 302-79-4/Tretinoin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treatment of rosacea with doxycycline monohydrate.
Next Document: Developmental instability and working memory ability in children: a magnetic resonance spectroscopy ...